- Home
- NBTB vs ACAD Comparison
NBTB vs ACAD Comparison
Compare NBTB & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTB
- ACAD
- Stock Information
- Founded
- NBTB 1856
- ACAD 1993
- Country
- NBTB United States
- ACAD United States
- Employees
- NBTB N/A
- ACAD N/A
- Industry
- NBTB Major Banks
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- NBTB Finance
- ACAD Health Care
- Exchange
- NBTB Nasdaq
- ACAD Nasdaq
- Market Cap
- NBTB 2.2B
- ACAD 2.5B
- IPO Year
- NBTB N/A
- ACAD 2004
- Fundamental
- Price
- NBTB $39.71
- ACAD $22.71
- Analyst Decision
- NBTB Buy
- ACAD Buy
- Analyst Count
- NBTB 3
- ACAD 16
- Target Price
- NBTB $52.33
- ACAD $27.00
- AVG Volume (30 Days)
- NBTB 180.5K
- ACAD 1.6M
- Earning Date
- NBTB 07-21-2025
- ACAD 08-05-2025
- Dividend Yield
- NBTB 3.42%
- ACAD N/A
- EPS Growth
- NBTB 17.05
- ACAD N/A
- EPS
- NBTB 3.03
- ACAD 1.37
- Revenue
- NBTB $569,473,000.00
- ACAD $996,283,000.00
- Revenue This Year
- NBTB $26.51
- ACAD $13.39
- Revenue Next Year
- NBTB $12.04
- ACAD $10.59
- P/E Ratio
- NBTB $13.19
- ACAD $16.65
- Revenue Growth
- NBTB 13.26
- ACAD 22.42
- 52 Week Low
- NBTB $35.54
- ACAD $13.40
- 52 Week High
- NBTB $52.44
- ACAD $25.23
- Technical
- Relative Strength Index (RSI)
- NBTB 34.35
- ACAD 66.04
- Support Level
- NBTB $40.75
- ACAD $21.35
- Resistance Level
- NBTB $42.95
- ACAD $22.69
- Average True Range (ATR)
- NBTB 0.87
- ACAD 0.76
- MACD
- NBTB -0.22
- ACAD -0.13
- Stochastic Oscillator
- NBTB 4.14
- ACAD 70.76
About NBTB NBT Bancorp Inc.
NBT Bancorp Inc is a financial holding company that operates through its subsidiaries. The company's principal sources of revenue include management fees and dividends it receives through its subsidiaries. Its business, predominantly conducted through NBT Bank, consists of providing commercial banking, retail banking, and wealth management services to customers in its market area, which includes upstate New York, northeastern Pennsylvania, southern New Hampshire, western Massachusetts, Vermont, southern Maine, and central and northwestern Connecticut. The company's reportable segments are Banking and Retirement Plan Administration. A majority of its revenue is generated from the Banking segment.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.